Dr William E Bowles, DO | |
6051 Us Hwy 49, Hattiesburg, MS 39401 | |
(601) 288-2690 | |
(601) 288-2695 |
Full Name | Dr William E Bowles |
---|---|
Gender | Male |
Speciality | General Surgery |
Experience | 38 Years |
Location | 6051 Us Hwy 49, Hattiesburg, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902805120 | NPI | - | NPPES |
64024748 | Medicaid | KY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 2474 (Kentucky) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Forrest General Hospital | Hattiesburg, MS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Fgh Trauma Surgery Clinic | 7517916331 | 12 |
News Archive
GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
According to a major new U.S. study, women who have heart attacks are more likely to survive if they are treated by a female doctor.
› Verified 2 days ago
Entity Name | Fgh Trauma Surgery Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1427090398 PECOS PAC ID: 7517916331 Enrollment ID: O20050119000801 |
News Archive
GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
According to a major new U.S. study, women who have heart attacks are more likely to survive if they are treated by a female doctor.
› Verified 2 days ago
Entity Name | Crossgates Hma Medical Group Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639401524 PECOS PAC ID: 8628100427 Enrollment ID: O20100714000431 |
News Archive
GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
According to a major new U.S. study, women who have heart attacks are more likely to survive if they are treated by a female doctor.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr William E Bowles, DO Po Box 16389, Hattiesburg, MS 39404 Ph: (601) 288-2690 | Dr William E Bowles, DO 6051 Us Hwy 49, Hattiesburg, MS 39401 Ph: (601) 288-2690 |
News Archive
GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
According to a major new U.S. study, women who have heart attacks are more likely to survive if they are treated by a female doctor.
› Verified 2 days ago
Dr. William Duncan Donald Iii, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6051 Us Hwy 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Ralph E Abraham, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5660 Fax: 601-268-5759 | |
Petra R Schneider-redden, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 421 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-261-3690 Fax: 601-261-3684 | |
Dr. Matthew Christopher Byrnes, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5650 Fax: 601-579-5240 | |
Dr. Cesar R Romero, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Dr. Kirk J Banquer, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Rachel Kaitlin Rosado, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5660 |